Complete financial analysis of CanBas Co., Ltd. (4575.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CanBas Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Westwing Group SE (WEW.DE) Income Statement Analysis – Financial Results
- Tremor International Ltd (TRMR) Income Statement Analysis – Financial Results
- Nihon Falcom Corporation (3723.T) Income Statement Analysis – Financial Results
- PuriflOH Limited (PUFLF) Income Statement Analysis – Financial Results
- Walchand PeopleFirst Limited (WALCHPF.BO) Income Statement Analysis – Financial Results
CanBas Co., Ltd. (4575.T)
About CanBas Co., Ltd.
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 108.95M | 110.00M |
| Cost of Revenue | 984.00M | 671.00M | 608.00M | 430.00M | 442.00M |
| Gross Profit | -984.00M | -671.00M | -608.00M | -321.06M | -332.00M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -294.69% | -301.82% |
| Research & Development | 983.00M | 671.04M | 607.78M | 430.24M | 442.21M |
| General & Administrative | 57.00M | 294.92M | 238.66M | 226.38M | 234.60M |
| Selling & Marketing | 134.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 191.00M | 294.92M | 238.66M | 226.38M | 234.60M |
| Other Expenses | -896.00M | -9.00K | -63.14M | 6.00K | -816.00K |
| Operating Expenses | 278.00M | 965.96M | 846.44M | 656.62M | 676.80M |
| Cost & Expenses | 1.26B | 965.96M | 846.44M | 656.62M | 676.80M |
| Interest Income | 32.00K | 21.00K | 17.00K | 38.00K | 159.00K |
| Interest Expense | 0.00 | 1.17M | 5.68M | 7.50M | 5.00M |
| Depreciation & Amortization | 1.26B | -315.93M | -2.21M | 62.00K | -1.89M |
| EBITDA | 53.65M | -1.24B | -848.65M | -522.28M | -566.54M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -502.65% | -516.99% |
| Operating Income | -1.26B | -965.97M | -846.44M | -547.67M | -566.80M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -502.70% | -515.27% |
| Total Other Income/Expenses | 54.00M | -277.86M | -7.89M | 17.89M | -4.74M |
| Income Before Tax | -1.21B | -1.24B | -854.33M | -529.78M | -571.54M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -486.29% | -519.58% |
| Income Tax Expense | 1.00M | 1.25M | 1.25M | 1.25M | 1.25M |
| Net Income | -1.21B | -1.24B | -855.58M | -531.03M | -572.79M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -487.43% | -520.72% |
| EPS | -67.87 | -83.03 | -88.32 | -70.02 | -83.64 |
| EPS Diluted | -67.87 | -83.03 | -88.32 | -70.02 | -83.64 |
| Weighted Avg Shares Out | 17.81M | 14.98M | 9.69M | 7.58M | 6.85M |
| Weighted Avg Shares Out (Dil) | 17.81M | 14.98M | 9.69M | 7.58M | 6.85M |
Source: https://incomestatements.info
Category: Stock Reports